New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 18, 2013
12:57 EDTMCPMolycorp January weekly calls active on renewed takeover chatter
Molycorp January 9 and 10 weekly calls are active on total call volume of 14K (7K puts). January weekly call option implied volatility is at 69, February and March is at 71; compared to its 26-week average of 72 according to Track Data. Active call volume suggests traders taking positions for large price movement following renewed takeover chatter.
News For MCP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 6, 2015
05:51 EDTMCPStocks with implied volatility movement; CRM MCP
Stocks with implied volatility movement; Salesforce (CRM) 64, Molycorp (MCP) 229 according to iVolatility.
April 24, 2015
09:20 EDTMCPOn The Fly: Pre-market Movers
UP AFTER EARNINGS: eHealth (EHTH), up 24.7%... Starbucks (SBUX), up 4.2%... Microsoft (MSFT), up 5.2%... Google (GOOG, GOOGL), up 3.2% and up 3.7%, respectively... Amazon (AMZN), up 12% after reporting quarterly results and announcing shopping app for Apple Watch... Gigamon (GIMO), up 16.5%... Juniper Networks (JNPR), up 6.6%. ALSO HIGHER: Molycorp (MCP), up 10.2% following a Bloomberg report that China's export tax decision may boost rare earth demand... Mattel (MAT), up 4.4% after being upgraded to Buy from Neutral at Goldman... Innocoll (INNL), up 13.1% after 3.3M share Secondary priced at $9.00... Cytosorbents (CTSO), up 9.7% after CEO comments on CytoSorb in letter to shareholders. DOWN AFTER EARNINGS: Biogen (BIIB), down 4.7%... Altera (ALTR), down 1.7%... Pandora (P), down 4%... ResMed (RMD), down 8.7%... Xerox (XRX), down 4.7%... HomeAway (AWAY), down 3.6% after reporting quarterly results and departure of officers. ALSO LOWER: Ubiquiti (UBNT), down 14.4% following CFO resignation and preliminary third quarter results... 3D Systems (DDD), down 10.4% after reporting preliminary first quarter results... StemCells (STEM), down 23.2% after filing to sell common stock... Aerie Pharmaceuticals (AERI), down 54.7% after Rhopressa Phase 3 trial did not meet primary endpoint.
09:04 EDTMCPLynas: China's export tax decision may boost rare earth demand, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use